ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
about
Aclidinium bromide for stable chronic obstructive pulmonary diseasePositioning new pharmacotherapies for COPDClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseIs aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled StudiesEffect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials.Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.Clinical use of aclidinium in patients with COPD.The role of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression.Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium.Long-acting muscarinic antagonists.Updates in the management of stable chronic obstructive pulmonary disease.Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized StudiesBringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Safety of inhaled long-acting anti-muscarinic agents in COPD.Long-Acting Bronchodilator Use in the Management of Stable COPD: A Review.Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
P2860
Q24193506-ADAD323F-279A-4E81-8B69-C90E64089E3FQ26798659-E8357636-B982-46B9-B885-95313DAA4456Q27023223-74771BFC-E7C5-4803-BFAE-37747D4C9C0EQ30365242-9BF2B689-06E6-41BF-B1FF-0A6BE91B0E51Q35914818-1839E126-136B-484A-B0D4-4FB40698E19FQ36307097-AD8A9225-0A8C-4CCE-A4A0-0A71322FB674Q37003186-0378C7A4-7A1D-4B88-8363-73AD7872DA26Q37494942-D3788F44-2CF2-4C66-B609-3116EBE02793Q37521969-DE7C3B82-37B1-4F72-93FA-35C022A97D63Q37698624-91C1CB29-50E5-4971-AEDA-278EEF65973AQ38210538-6587F289-E6C6-446E-988D-4DC8224ACC2BQ38287153-89720CE5-01BA-4184-A910-CD7A8BE2C301Q38317463-4649CD2F-2A1E-4732-84FF-256468479320Q38344780-3588084B-09E6-4C32-8813-2F79B4A3FDBCQ38537326-442A9825-D6A5-4EF0-AF34-157E6E4F38E5Q38578596-335DCACE-F712-45E8-835C-D8AC4CA03423Q38604641-6468D437-445C-481F-A554-C00B16E64157Q38604650-2DDE481B-A371-4007-9756-30FA0052B662Q38751226-ABB047D0-2F9D-4798-B6EB-3E6C1648DDB1Q39232425-21806B16-207C-4EF2-9202-B42072F482A0Q47282204-F62C8A62-040D-48F2-B025-1D6BA0059842Q51595221-A1DF7562-4F93-4E35-B8C4-A1DC9474FFE1Q52599393-EE5A0182-AC4E-4DA9-B063-11723B9D013FQ57817177-86002340-268D-454B-BDCA-039249741671
P2860
ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
ACCORD COPD II: a randomized c ...... ve pulmonary disease patients.
@en
ACCORD COPD II: a randomized c ...... ve pulmonary disease patients.
@nl
type
label
ACCORD COPD II: a randomized c ...... ve pulmonary disease patients.
@en
ACCORD COPD II: a randomized c ...... ve pulmonary disease patients.
@nl
prefLabel
ACCORD COPD II: a randomized c ...... ve pulmonary disease patients.
@en
ACCORD COPD II: a randomized c ...... ve pulmonary disease patients.
@nl
P2093
P2860
P1476
ACCORD COPD II: a randomized c ...... ve pulmonary disease patients.
@en
P2093
Brian T Maurer
Cynthia F Caracta
Esther Garcia Gil
Gary T Ferguson
Ludmyla Rekeda
Paul D Scanlon
Stephen I Rennard
P2860
P304
P356
10.1007/S40261-013-0138-1
P577
2013-12-01T00:00:00Z